Guided Therapeutics (GTHP) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to -$742000.0.
- Guided Therapeutics' Income towards Parent Company fell 1345.57% to -$742000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.6 million, marking a year-over-year decrease of 2236.17%. This contributed to the annual value of -$2.4 million for FY2024, which is 3072.51% up from last year.
- As of Q3 2025, Guided Therapeutics' Income towards Parent Company stood at -$742000.0, which was down 1345.57% from -$811000.0 recorded in Q2 2025.
- Guided Therapeutics' 5-year Income towards Parent Company high stood at $68000.0 for Q3 2021, and its period low was -$1.8 million during Q4 2022.
- For the 5-year period, Guided Therapeutics' Income towards Parent Company averaged around -$745000.0, with its median value being -$677000.0 (2023).
- As far as peak fluctuations go, Guided Therapeutics' Income towards Parent Company surged by 8467.92% in 2021, and later crashed by 172058.82% in 2022.
- Quarter analysis of 5 years shows Guided Therapeutics' Income towards Parent Company stood at -$444000.0 in 2021, then plummeted by 306.98% to -$1.8 million in 2022, then soared by 78.64% to -$386000.0 in 2023, then crashed by 68.91% to -$652000.0 in 2024, then dropped by 13.8% to -$742000.0 in 2025.
- Its Income towards Parent Company stands at -$742000.0 for Q3 2025, versus -$811000.0 for Q2 2025 and -$427000.0 for Q1 2025.